Thomas Karikari

Has grant

Assistant Professor of Psychiatry

University of Pittsburgh

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Thomas Karikari is an Assistant Professor of Psychiatry at the University of Pittsburgh, USA. His research primarily focuses on neurodegenerative diseases, with recent articles examining proteomic signatures, plasma biomarkers related to Alzheimer's disease, and multimodal neuroimaging. He has contributed to studies on the diagnostic accuracy of biomarkers and dementia risk reduction strategies, particularly in diverse populations.

Recent Grants

Grant: Close

Neurochemical basis of ethnic diversity in Alzheimer diagnostics

Open Date: 2022-02-01

Close Date: 2025-01-01

Grant: Close

Blood biomarker profiles to distinguish amyloid-first and tau-first molecular subtypes of Alzheimer’s disease: a personalized medicine approach

Open Date: 2022-01-01

Close Date:

Grant: Close

Phospho-tau181: a new blood test to predict Alzheimer’s disease

Open Date: 2020-01-01

Close Date:

Grant: Close

Plasma phospho-tau 181 and 217 as novel biomarkers to differentiate Lewy Body diseases from Parkinson's disease

Open Date: 2020-01-01

Close Date: 2021-01-01

Grant: Close

New blood-based biomarkers for differential diagnosis of Parkinson's disorders

Open Date: 2020-01-01

Close Date: 2021-01-01

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (22)

Nicholas Ashton

Banner Alzheimer’s Institute

UNITED STATES

Thomas Karikari

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (30)

Proteomic signatures of corona and herpes viral antibodies identify IGDCC4 as a mediator of neurodegeneration

Comparison of Plasma p-tau217 and [ 18 F]FDG-PET for Identifying Alzheimer Disease in People With Early-Onset or Atypical Dementia

Novel plasma biomarkers of amyloid plaque pathology and cortical thickness: Evaluation of the NULISA targeted proteomic platform in an ethnically diverse cohort

A novel ultrasensitive assay for plasma p‐tau217: Performance in individuals with subjective cognitive decline and early Alzheimer's disease

Biomarker-based staging of Alzheimer disease: rationale and clinical applications

Association of plasma biomarkers of Alzheimer's disease and related disorders with cognition and cognitive decline: The MYHAT population‐based study

Personalized whole-brain neural mass models reveal combined Aβ and tau hyperexcitable influences in Alzheimer’s disease

Plasma phosphorylated-tau217 is increased in Niemann–Pick disease type C

Dementia risk reduction in the African context: Multi‐national implementation of multimodal strategies to promote healthy brain aging in Africa (the Africa‐FINGERS project)

Data-driven CSF biomarker profiling: imaging and clinical outcomes in a cohort at risk of Alzheimer's disease.

Multimodal neuroimaging biomarkers and subtle cognitive decline in a population-based cohort without dementia.

Influence of medical conditions on the diagnostic accuracy of plasma p-tau217 and p-tau217/Aβ42.

Sex differences in the trajectories of plasma biomarkers, brain atrophy, and cognitive decline relative to amyloid onset.

Diagnosis of Alzheimer's disease using plasma biomarkers adjusted to clinical probability.

APOE ε4 associates with microglial activation independently of Aβ plaques and tau tangles

Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease

Association of Serum Brain-Derived Tau With Clinical Outcome and Longitudinal Change in Patients With Severe Traumatic Brain Injury.

Longitudinal blood biomarker trajectories in preclinical Alzheimer's disease.

Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease.

Preanalytical stability of plasma/serum brain-derived tau.

Longitudinal changes in Alzheimer's-related plasma biomarkers and brain amyloid.

Tau in cerebrospinal fluid induces neuronal hyperexcitability and alters hippocampal theta oscillations

Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.

Alzheimer Disease Blood Biomarkers in Patients With Out-of-Hospital Cardiac Arrest.

Levels of plasma brain‐derived tau and p‐tau181 in Alzheimer's disease and rapidly progressive dementias

Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study.

Menopausal Vasomotor Symptoms and Plasma Alzheimer's Disease Biomarkers.

Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-β positive individuals.

Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.

APOEε4 potentiates amyloid β effects on longitudinal tau pathology.

Collaborators (22)

Nicholas Ashton

Przemysław Radosław Kac

William Klunk

Michael Schöll

Rebecca Gottesman

Firoza Zubeida Lussier

Suzanne Schindler

Junhao WEN

Imre Lengyel

Adam Spira

Josef Coresh

Mira Karrasch

Timothy Hohman

Emmanuel COGNAT

Andrea Mastrangelo

Melissa Murray

Hlin Kvartsberg

Danielle Taylor-te Vruchte

Fernando Gonzalez-Ortiz

Brion Maher

Rui Magalhães

Murat Bilgel

Make your next move.